NCT07204548

The IVO-LUNG Study

Ivonescimab Consolidation After Concurrent/Sequential Chemoradiation for Unresectable Stage III NSCLC- A Phase II Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This Phase II, open-label, single-arm study evaluates the efficacy and safety of one-year Ivonescimab consolidation therapy in patients with unresectable Stage III NSCLC who have not progressed after definitive chemoradiotherapy.

Detailed description

This is an open-label, single-arm, Phase II clinical study. The study plans to enroll previously untreated patients with Stage III (AJCC 8th edition) unresectable NSCLC who have not progressed after definitive concurrent/sequential chemoradiotherapy (≥2 cycles of platinum-based doublet chemotherapy). Induction therapy prior to concurrent or sequential chemoradiation is permitted. Subjects will receive Ivonescimab consolidation therapy for one year. The study aims to evaluate the efficacy and safety of Ivonescimab as consolidation therapy, alongside the exploration of efficacy-related biomarkers.

Conditions

• Non Small Cell Lung Cancer (Stage III)

Interventions

Type	Name	Description
DRUG	Ivonescimab	Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy

Timeline

• Start date: 2025-10-01
• Primary completion: 2027-10-01
• Completion: 2029-10-01
• First posted: 2025-10-02
• Last updated: 2025-10-02

Locations

1 site across 1 country: China